1 / 197 爱博诺德（北京）医疗科技股份有限公司2025 年半年度报告 公司代码：688050 公司简称：爱博医疗 爱博诺德（北京）医疗科技股份有限公司 2025 年半年度报告 爱博诺德（北京）医疗科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会董事高级管理人员保证半年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 本公司已在本报告中详细阐述在生产经营过程中可能面临的各种风险因素，敬请参阅"第三 节管理层讨论与分析"之"四、风险因素"相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人解江冰、主管会计工作负责人郭彦昌及会计机构负责人（会计主管人员）郭彦 昌声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述，不构成本公司对投资者的承诺，敬请 投资者注意 ...

Summary of Key Points Core Viewpoint - Aibo Medical experienced significant trading activity on August 25, with a total of 266,000 shares traded through block transactions, amounting to 19.434 million yuan, at a price of 73.06 yuan per share, reflecting a discount of 7.40% compared to the closing price of the day [2]. Trading Activity - On August 25, Aibo Medical had 6 block trades with a total trading volume of 266,000 shares and a total transaction value of 19.434 million yuan [2]. - The average transaction price was 73.06 yuan, which is 7.40% lower than the closing price of the day [2]. - Institutional trading desks participated in 2 of the transactions, with a total transaction value of 4.2375 million yuan, indicating a net purchase of the same amount [2]. Recent Trading Trends - Over the past three months, Aibo Medical has recorded a total of 27 block trades, with a cumulative transaction value of 150 million yuan [2]. - The closing price of Aibo Medical on the reporting day was 78.90 yuan, showing an increase of 1.52% [2]. - The stock had a turnover rate of 2.59% and a total trading volume of 386 million yuan for the day, with a net outflow of 5.1478 million yuan in main funds [2]. - In the last five days, the stock has increased by 1.53%, with a total net inflow of 9.8642 million yuan [2]. Margin Trading Data - The latest margin financing balance for Aibo Medical is 547 million yuan, which has decreased by 21.2109 million yuan over the past five days, representing a decline of 3.73% [2].

Core Viewpoint - Aibo Medical's stock price increased by 1.52% to 78.90 yuan as of August 25, 2025, with significant trading activity noted [1] Group 1: Stock Performance - Aibo Medical's stock opened at 77.72 yuan, reached a high of 79.11 yuan, and a low of 77.72 yuan, with a trading range of 1.79% on the same day [1] - The total trading volume for the day was 3.86 billion yuan [1] Group 2: Business Overview - Aibo Medical specializes in the research, production, and sales of ophthalmic medical devices, including artificial lenses and orthokeratology lenses [1] - The company operates in sectors such as medical devices and specialized innovation [1] Group 3: Trading Activity - On August 25, Aibo Medical experienced six block trades totaling 266,000 shares, amounting to 19.434 million yuan, with an average transaction price of 73.06 yuan, reflecting a discount of 7.40% compared to the closing price [1] - Institutional accounts purchased 58,000 shares, with a transaction value of 4.2375 million yuan [1] Group 4: Capital Flow - On the same day, Aibo Medical saw a net outflow of 1.6362 million yuan in main funds, while the net inflow over the past five days was 2.6767 million yuan [2]

Company Overview - Aibo Medical's closing price on August 25 was 78.9 yuan, with an increase of 1.52%, resulting in a rolling PE ratio of 40.36 times and a total market value of 15.26 billion yuan [1] - The company ranks 77th in the medical device industry, which has an average PE ratio of 56.14 times and a median of 40.36 times [1] Institutional Holdings - As of the first quarter of 2025, 18 institutions hold shares in Aibo Medical, all of which are funds, with a total holding of 11.0688 million shares valued at 762 million yuan [1] Business Operations - Aibo Medical focuses on the independent research, production, sales, and related services of ophthalmic medical devices, with main products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] Financial Performance - In the latest quarterly report for Q1 2025, Aibo Medical achieved an operating revenue of 357 million yuan, representing a year-on-year increase of 15.07%, while net profit was 92.5581 million yuan, showing a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 8月25日，爱博医疗收涨1.52%，收盘价为78.90元，发生6笔大宗交易，合计成交量26.6万股，成交金额 1943.4万元。 第4笔成交价格为73.06元，成交3.00万股，成交金额219.18万元，溢价率为-7.40%，买方营业部为机构 专用，卖方营业部为国联民生证券股份有限公司北京金宝街证券营业部。 第5笔成交价格为73.06元，成交2.80万股，成交金额204.57万元，溢价率为-7.40%，买方营业部为机构 专用，卖方营业部为国联民生证券股份有限公司北京金宝街证券营业部。 第6笔成交价格为73.06元，成交10.00万股，成交金额730.60万元，溢价率为-7.40%，买方营业部为华泰 证券股份有限公司深圳益田路荣超商务中心证券营业部，卖方营业部为国联民生证券股份有限公司北京 金宝街证券营业部。 进一步统计，近3个月内该股累计发生27笔大宗交易，合计成交金额为1.5亿元。该股近5个交易日累计 上涨1.53%，主力资金合计净流出260.54万元。 责任编辑：小浪快报 第1笔成交价格为73.06元，成交5.00万股，成交金额36 ...

8月25日，爱博医疗大宗交易成交26.6万股，成交额1943.4万元，占当日总成交额的4.8%，成交价73.06元，较市场收盘价78.9元折价7.4%。 | 交易日期 | 证券简称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-25 | 爱博医疗 | 688050 | 73.06 | 730.6 | 10 | 华泰证券股份有限 | 国联民生证券股份 | | | | | | | | 公司深圳益田路荣 | 有限公司北京金宝 | | | | | | | | 超商务中心证券营 | 街证券营业部 | | | | | | | | 业部 | | | 2025-08-25 | 爱博医疗 | 688050 | 73.06 | 365.3 | ર | 中信证券股份有限 | 国联民生证券股份 | | | | | | | | 公司上海分公司 | 有限公司北京金宝 | | | | | | | | | 街证券营业部 | | 2025-08-25 | 爱博医疗 ...

Group 1: Ice Wheel Environment (000811) - The company focuses on providing advanced system solutions and lifecycle services in the energy and power sectors, with products including compressors and heat exchangers operating in the temperature range of -271℃ to 200℃ [1] - In the first half of the year, the low-temperature refrigeration segment generated revenue of 1.73 billion yuan, accounting for 55% of total revenue, while the HVAC segment generated 1.2 billion yuan, accounting for 39% [1] - The company supplies cooling equipment for data centers, and its products have been included in the Ministry of Industry and Information Technology's directory of advanced applicable technologies for national green data centers [1] Group 2: Lite Optoelectronics - In the first half of 2025, the company achieved revenue of 292 million yuan, a year-on-year increase of 18.84%, and a net profit of 126 million yuan, up 36.74% year-on-year [2] - The growth is attributed to rising demand in the OLED market and the company's cost reduction and efficiency improvement efforts [2] - The company is expanding its OLED terminal materials product line and accelerating the construction of its 8.6-generation line, which is expected to significantly boost demand for organic light-emitting materials [2] Group 3: Opto - In the first half of 2025, the company reported revenue of 682.56 million yuan, a year-on-year increase of 30.68%, and a net profit of 145.99 million yuan, up 28.80% [3] - The company has made progress in the smart robotics sector and established a robotics division, enhancing its visual solution offerings [3] - The machine vision industry is projected to exceed 21 billion yuan in market size by 2025, with a compound annual growth rate of approximately 20% from 2024 to 2028 [3] Group 4: Longli Technology (300752) - The company experienced revenue growth in the first half of 2025, but profits declined due to increased capacity construction and personnel costs, leading to short-term operational pressure [4] - The company’s LIPO technology products have begun mass production, with the mobile phone project entering mass production in the third quarter [4] - As a leading player in Mini-LED technology for automotive displays, the company is positioned for rapid growth in this sector, with recent products featuring its Mini-LED technology [4] Group 5: Longsheng Fund - As of now, the fund has an asset management scale of 96.413 billion yuan, ranking 62nd among 210 funds, with 65.591 billion yuan in non-monetary public funds [5] - The fund manages 140 public funds and has 22 fund managers, ranking 55th and 63rd respectively [5] - The best-performing fund in the past year is the Longsheng Urbanization Theme Mixed A fund, with a net value increase of 110.67% [5]

Group 1 - The medical device industry experienced a slight increase of 0.07% on August 21, with a net outflow of 596 million yuan in main capital [1] - Among the component stocks, 55 stocks rose while 41 stocks fell [1] - The companies with the highest net outflow of main capital included Xinhua Medical (11.58 million yuan), Libang Instruments (10.77 million yuan), and Jiukang Bio (10.73 million yuan) [1] Group 2 - The latest prices and performance of selected medical companies include: Meihua Medical at 23.41 with an increase of 8.09% and a net inflow of 6.44 million yuan [2] - Mindray Medical at 245.71 with an increase of 3.87% and a net inflow of 879.86 million yuan [2] - Other notable companies include Yingke Medical at 37.43 with an increase of 1.08% and a net inflow of 599.81 million yuan, and Aibo Medical at 77.31 with an increase of 1.15% and a net inflow of 4360.64 million yuan [2]

8月18日，沪深两融数据显示，爱博医疗上周累计获融资净买入额1720.87万元，居两市第470位，上周 融资买入额2.51亿元，偿还额2.33亿元。 天眼查商业履历信息显示，爱博诺德(北京)医疗科技股份有限公司，成立于2010年，位于北京市，是一 家以从事医药制造业为主的企业。企业注册资本19340.3175万人民币，实缴资本18954.4528万人民币。 公司法定代表人为解江冰。 通过天眼查大数据分析，爱博诺德(北京)医疗科技股份有限公司共对外投资了20家企业，参与招投标项 目222次，知识产权方面有商标信息717条，专利信息165条，此外企业还拥有行政许可93个。 来源：金融界 爱博医疗所属概念板块包括：医疗器械、北京板块、专精特新、沪股通、上证380、融资融券、机构重 仓、医疗器械概念。 资金流方面，爱博医疗近5日主力资金流出1.18亿元，区间跌幅6.39%；近10日主力资金流出2.13亿元， 区间跌幅6.2%。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a total A-share increase of 2.04% and a decline of 0.84% in the biotechnology sector [1][30]. - The brain-computer interface (BCI) industry is rapidly developing, supported by recent government policies and successful clinical trials, indicating significant growth potential [2][11]. - The report emphasizes the importance of innovative drugs and their supporting infrastructure, highlighting the positive impact of adjustments in medical insurance and commercial health insurance on domestic innovative drug sales [3][39]. Summary by Sections Market Performance - The overall A-share market increased by 2.04%, while the biotechnology sector decreased by 0.84%, indicating a weaker performance relative to the market [1][30]. - The current price-to-earnings (P/E) ratio for the pharmaceutical sector is 38.77x, which is at the 80.28th percentile of its historical valuation over the past five years [1][35]. Brain-Computer Interface Industry - The BCI industry is characterized by a growing number of supportive policies and technological advancements, with a focus on both invasive and non-invasive methods [2][11]. - The market for non-invasive BCIs is the primary research direction, accounting for 86% of the market share [11][16]. - The potential market size for serious medical applications of BCIs is estimated between $15 billion and $85 billion, while consumer medical applications could reach $25 billion to $60 billion [16]. Key Companies and Investment Recommendations - **Mindray Medical (300760.SZ)**: Rated "Outperform" with projected net profits increasing from 116.7 billion in 2024 to 161.9 billion in 2027 [4]. - **WuXi AppTec (603259.SH)**: Rated "Outperform" with expected net profits rising from 93.5 billion in 2024 to 145.1 billion in 2027 [4]. - **Aier Eye Hospital (300633.SZ)**: Rated "Outperform" with a focus on expanding its service network and enhancing service prices [39]. - **Huitai Medical (688617.SH)**: Rated "Outperform" with a strong focus on electrophysiology and interventional medical devices [40]. - **Innovative Medical (002173.SZ)**: Rated "Outperform" with ongoing clinical trials and expected registration of medical devices [39].